Trimodality of isoniazid elimination: Phenotype and genotype in patients with tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 155, Issue 5, 1997, Pages 1717-1722

  Parkin, Donald P ^a   Vandenplas, Santie ^b   Botha, Frederik J H ^b   Vandenplas, Michel L ^b   Seifart, Heiner I ^b   Van Helden, Paul D ^b   Van Der Walt, Barend J ^b   Donald, Peter R ^b   Van Jaarsveld, Pieter P ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ISONIAZID;

ACETYLATOR PHENOTYPE; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PENETRANCE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0030914911     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.155.5.9154882     Document Type: Article

References (34)

1. Weber, W. W., and D. W. Hein. 1979. Clinical pharmacokinetics of isoniazid. Clin. Pharmacokinet. 4:401-422.
2. Ellard, G. A. 1984. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 65:211-227.
3. Dickinson, D. S., W. C. Bailey, B. I. Hirschowitz, S. J. Soong, L. Eidus, and M. M. Hodgkin. 1981. Risk factors for isoniazid (INH)-induced liver dysfunction. J. Clin. Gastroenterol. 3:271-279.
4. Deguchi, T., M. Mashimo, and T. Suzuki. 1990. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 265:12757-12760.
5. Mandell, G. L., and W. A. Petri. 1996. Antimicrobial agents. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, and A. G. Gilman, editors. The Pharmacological Basis of Therapeutics, 9th ed. McGraw Hill, New York. 1155-1159.
6. Marais, J. S. 1957. The Cape Coloured People 1652-1932, 1st ed. Witwatersrand University Press, Johannesburg. 1-31.
7. Seifart, H. I., W. L. Gent, D. P. Parkin, P. P. Van Jaarsveld, and P. R. Donald. 1995. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J. Chromatogr. B. 674:269-275.
8. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, New York.
9. Sambrook, J., E. F. Fritsch, and I. Maniatis. 1985. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 9.20-9.21.
10. Hickman, D., and E. Sim. 1991. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem. Pharmacol. 42:1007-1014.
11. Hickman, D., A. Risch, J. P. Camilleri, and E. Sim. 1992. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 2:217-226.
12. Vatsis, K. P., W. W. Weber, D. A. Bell, J.-M. Dupret, D. A. Price Evans, D. M. Grant, D. W. Hein, H. J. Lin, U. A. Meyer, M. V. Relling, E. Sim, T. Suzuki, and Y. Yamazoe. 1995. Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1-17.
13. Hein, D. W., M. A. Doll, T. D. Rustan, and R. J. Ferguson. 1995. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 55:3531-3536.
14. Lin, H. J., C.-Y. Han, B. K. Lin, and S. Hardy. 1994. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4:125-134.
15. Sunahara, S., M. Urano, and M. Ogawa. 1961. Genetical and geographic studies on isoniazid inactivation. Science 134:1530.
16. Ellard, G. A. 1976. A slow-release preparation of isoniazid: pharmacological aspects. BIUAT 51:143-154.
17. Lin, H. J., C.-Y. Han, B. K. Lin, and S. Hardy. 1993. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am. J. Hum. Genet. 52:827-834.
18. Cascorbi, I., N. Drakoulis, J. Brockmöller, A. Maurer, K. Sperling, and I. Roots. 1995. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 57:581-592.
19. Schloot, W., K. G. Blume, and H. W. Goedde. 1967. Studies on isoniazid conversion in Thailand. Humangenetik 4:274-279.
20. Ellard, G. A., and P. T. Gammon. 1972. The pharmacokinetics of isoniazid metabolism in man. In Advances in Antimicrobial and Antineoplastic Chemotherapy. Proceedings of the VIIth International Congress of Chemotherapy Prague, 1971, Urban and Schwarzenberg, Munich. 45.
21. Peretti, E., G. Karlaganis, and B. H. Lauterburg. 1987. Acetylation of acetylhydrazine, the toxic metabolite of isoniazid in humans. Inhibition by concomitant administration of isoniazid. J. Pharmacol. Exp. Ther. 244:686-689.
22. Weber, W. W. 1987. The Acetylator Genes and Drug Response. Oxford University Press, New York.
23. Jindani, A., V. R. Aber, E. A. Edwards, and D. A. Mitchison. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-948.
24. Sirgel, F. A., F. J. H. Botha, D. P. Parkin, B. W. Van De Wal, P. R. Donald, P. K. Clark, and D. A. Mitchison. 1993. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J. Antimicroh. Chemother. 32:867-875.
25. Botha, F. J. H., F. A. Sirgel, D. P. Parkin, B. W. Van De Wal, P. R. Donald, and D. A. Mitchison. 1996. Early bactericidal activity of ethambutol, pryazinamide and a fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S. Afr. Med. J. 86:155-158.
26. Heifets, L. B. 1994. Antimycobacterial drugs. Semin. Respir. Infect. 9:84-103.
27. Wood, A. J. J. 1993. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. 329:784-791.
28. Mitchison, D. A., and J. M. Dickinson. 1971. Laboratory aspects of intermittent drug therapy. Postgrad. Med. J. 47:737-741.
29. Elliott, A. M., S. E. Berning, M. D. Iseman, and C. A. Peloquin. 1995. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber. Lung Dis. 76:463-467.
30. Jenne, J. W., and W. H. Beggs. 1973. Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol and rifampicin. Am. Rev. Respir. Dis. 107:1013-1021.
31. Hart, C. A., N. J. Beeching, and B. I. Duerden, editors. 1996. Tuberculosis into the next century. J. Med. Microbiol. 44:1-34.
32. Berning, S. E., G. A. Huitt, M. D. Iseman, and C. A. Peloquin. 1992. Malabsorption of antituberculosis medications in patients with AIDS. N. Engl. J. Med. 327:1817-1818.
33. Heifets, L. B. 1988. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am. Rev. Respir. Dis. 137:1217-1222.
34. Bradford, W. Z., J. N. Martin, A. L. Reingold, G. F. Schecter, P. C. Hopewell, and P. M. Small. 1996. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 348: 928-931.